Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Diquafosol - Merck/Santen Pharmaceutical

Next Previous
Drug Profile

Diquafosol - Merck/Santen Pharmaceutical

Alternative Names: DE-089; DE-089C; Diquafosol sodium; Diquafosol tetrasodium; Diquas; Diquas ophthalmic solution; INS 365; KPY 998; Prolacria; STN-1008903

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Inspire Pharmaceuticals
  • Developer Inspire Pharmaceuticals; Meiji Seika Pharma; Santen Pharmaceutical
  • Class Antibronchitics; Antifibrotics; Expectorants; Eye disorder therapies; Polyphosphates; Small molecules; Uracil nucleotides
  • Mechanism of Action Purinoceptor P2U agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Dry eyes
  • Discontinued Bronchitis; Chronic obstructive pulmonary disease; Corneal ulcer; Cystic fibrosis

Most Recent Events

  • 28 Oct 2020 No recent reports of development identified for phase-I development in Dry-eyes in Taiwan (Ophthalmic, Liquid)
  • 28 Aug 2020 Santen Pharmaceutical initiates a phase IIIb trial in Dry eyes in Japan (JapicCTI205466)
  • 08 May 2020 Allergan has been acquired and merged into AbbVie

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top